Abstract
The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations at specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-ΔG-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in Phase II clinical trials. It is based on a replication competent vesicular stomatitis virus (VSV) platform. rVSV-ΔG-spike contains several spontaneously-acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma and delta variants, and show less than 3-fold reduction in neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain neutralizing antibody response against all tested variants. We suggest that BriLife® acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04608305
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Serum samples of BriLife® vaccinees were obtained from participants in a randomized, multi-center, placebo-controlled, dose-escalation phase II of an ongoing clinical trial, aimed to evaluate the safety, immunogenicity and potential efficacy of BriLife®, an rVSV-SARS-CoV-2-S vaccine (IIBR-100) in Adults (ClinicalTrials.gov - NCT04608305). This study was performed in compliance with International Council for Harmonisation (ICH) Good Clinical Practices (GCP), including the archiving of essential documents as well as the ethical principles of the Declaration of Helsinki. Serum samples of convalescent COVID-19 patients were collected by the National Blood Services of Magen David Adom in Israel within a protocol for plasma donation. All convalescent volunteers gave their informed consent to the National Blood services of Magen David Adom. The study was approved by the ethics committee of the Israeli Ministry of Health (0083-20-WOMC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
yfatyr{at}iibr.gov.il (Y.Y.-R.); noame{at}iibr.gov.il (N.E.); morlyf{at}iibr.gov.il (M.F.) hadast{at}iibr.gov.il (H.T.); boazp{at}iibr.gov.il (B.P.); hagita{at}iibr.gov.il (H.A.); sharonm{at}iibr.gov.il (S.M.); itaig{at}iibr.gov.il (I.G.); shayw{at}iibr.gov.il (S.W.); advam{at}iibr.gov.il (A.M.), tomeri{at}iibr.gov.il (T.I.), nirp{at}iibr.gov.il (N.P.).
inbarg{at}iibr.gov.il (I.C.G.), ofiri{at}iibr.gov.il (O.I.) adib{at}iibr.gov.il (A.B.D.), anatz{at}iibr.gov.il (A.Z.)
marinai{at}mdais.co.il (M.I.), eilats{at}mdais.co.il (E.S.)
michal.mandelboim{at}sheba.health.gov.il (M.M.)
CARACO{at}hadassah.org.il (Y.C)
noamb{at}iibr.gov.il
ranz{at}iibr.gov.il (R.Z.); hadarm{at}iibr.gov.il (H.M.)
dancohen{at}tauex.tau.ac.il (D.C.)
Omicron VOC data was added
Data Availability
All data produced in the present work are contained in the manuscript
